ArticleOncoTargets and therapy2014
A new inflammation index is useful for patients with esophageal squamous cell carcinoma.
Article in OncoTargets and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 5 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- The advanced lung cancer inflammation index is a prognostic factor for gastrointestinal cancer patients undergoing surgery: a systematic review and meta-analysis.World journal of surgical oncology · 2023Pooled it
- The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy.BMC cancer · 2023Pooled it
- Clinical significance of the advanced lung cancer inflammation index in gastrointestinal cancer patients: a systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Prognostic role of the advanced lung cancer inflammation index in cancer patients: a meta-analysis.World journal of surgical oncology · 2019Pooled it
- Prognostic Value of the Advanced Lung Cancer Inflammation Index in Patients with Lung Cancer: A Meta-Analysis.Disease markers · 2019Pooled it
- Relationship between the advanced lung cancer inflammation index (ALI) and all-cause and cause-specific mortality among patients with chronic obstructive pulmonary disease (COPD): a population-based study.BMC pulmonary medicine · 2026Article
- Anastomotic leakage after esophagogastric resection increases recurrence risk and impairs long-term survival - a propensity score-matched analysis.BMC surgery · 2026Article
- Prognostic impact of advanced lung cancer inflammation index and tumor load index in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy.Frontiers in immunology · 2026Article
- Advanced Lung Cancer Inflammation Index (ALI) as an Independent Predictor for Bronchiectasis Exacerbation Risks.Journal of inflammation research · 2026Article
- The Role of Advanced Lung Cancer Inflammation Index in Predicting COPD Exacerbation Risks.International journal of chronic obstructive pulmonary disease · 2026Article
- Advanced lung cancer inflammation index as a predictor of all-cause and cardiovascular mortality among patients with hypertension in the US.BMC cardiovascular disorders · 2025Article
- Association between advanced lung cancer inflammation index and all-cause mortality in critically ill patients with sepsis: analysis of the MIMIC-IV database.Scientific reports · 2025Article
- The association of the advanced lung cancer inflammation index with postoperative complications in patients undergoing lung resection for bronchiectasis.Journal of thoracic disease · 2025Article
- Cystathionine gamma-lyase as an inflammatory factor and its link with immune inflammation in hepatitis B virus-related liver disease.Scientific reports · 2025Article
- Prognostic value of inflammation and nutritional indicators for sinonasal squamous cell carcinoma: A single-center retrospective study.Laryngoscope investigative otolaryngology · 2025Article
- Impact of advanced lung cancer inflammation index on all-cause mortality among patients with heart failure: a systematic review and meta-analysis with reconstructed time-to-event data.Cardio-oncology (London, England) · 2025Review
- Prognostic Impact of Advanced Lung Cancer Inflammation Index (ALI) on Immunotherapy Outcomes in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicenter Post Hoc Analysis.Journal of inflammation research · 2025Article
- Nutritional status and systemic inflammation in COPD: prognostic value of the advanced lung cancer inflammation index.Frontiers in nutrition · 2025Article
- Association between advanced lung cancer inflammation index and acute gouty arthritis in Dalian, China: a cross-sectional study.Frontiers in nutrition · 2025Article
- The advanced lung cancer inflammation index has an L-shaped association with prognosis in American adults with metabolic dysfunction-associated fatty liver disease: a cohort study.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognostic value of inflammation indexes in esophageal cancer has not been established. Recent studies have shown that the advanced lung cancer inflammation index (ALI) is a useful predictive factor. The purpose of the current study was to determine whether the ALI is useful for predicting long-term survival in patients with esophageal squamous cell carcinoma (ESCC). PATIENTS AND
methodsA total of 293 patients who had undergone esophagectomy for ESCC were included. The ALI was calculated as body mass index × serum albumin/neutrophil-to-lymphocyte ratio. Then, patients were divided into two groups: ALI ≥18 and ALI <18. The Kaplan-Meier method was used to calculate the cancer-specific survival (CSS), and the difference was assessed by the log-rank test. Univariate and multivariate analyses were performed to evaluate the prognostic factors.
resultsIn our study, there were 120 patients with ALI <18 and 173 patients with ALI ≥18. ALI was significantly higher in patients with large tumors (P=0.028), poor differentiation (P=0.010), deep invasion (P=0.009), and nodal metastasis (P=0.004). The 5-year CSS was 34.5% in our study. Patients with ALI <18 had a significantly poorer 5-year CSS compared to ALI ≥18 (21.7% versus 43.4%, P<0.001). On multivariate analysis, we showed that the ALI was a significant predictive factor of CSS (P=0.024).
conclusionThe ALI is still a useful predictive factor for long-term CSS in patients with ESCC. However, the prognostic value of the ALI is yet to be formally tested within randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.